.jpg)
We are proud to announce that Virry VR complies with the NHS UK's DCB 0129 Standard of Clinical Safety. Prepared by the NHS Digital Clinical Safety team, DCB 0129 is designed to help manufacturers of Health IT software evidence the clinical safety of their products.
Virry VR is classified as a Class 1 Medical Device with the MHRA, as a product intended for the prevention, treatment and/or alleviation of stress and anxiety, as well as neurodegenerative and neuropsychiatric symptoms associated with conditions, such as dementia, Alzheimer's, and ADHD and is CE accredited.
Virry VR was developed with psychologist Dr Gail Melson, of Perdue University, and Prof. Jeremy Bailenson of Stanford University, to ensure we created a VR product that is safe and emotionally beneficial to use.
Virry Life is compatible with Pico G2 4K headsets. Pico headsets are designed to be easy to clean and are hygienic for shared use. The equipment can either be taken apart and easily wiped down between uses, or solutions such as Cleanbox Technology, which can kill 99.999% of bacteria, viruses, and fungi in 60 seconds, can be used.
User feedback was collected during the development phase of Virry VR. We ran test groups of various ages at a Virry VR Experience space, set up at our studio in London, to trail the product test build and collect feedback. This feedback was used by the Virry team to amend our design and ensure we built a product that was easy and intuitive to use by all ages.
.svg){kind=icon}
.svg){kind=icon}
.jpg)
A study led by Vivian Hill, from the Department of Psychology and Human Development at the UCL Institute of Education, will look into Virry VR’s effectiveness as a non-medicinal treatment on children with ADHD. A pilot study is currently being carried out on a group of children in Year 1 who have been identified with complex behavioural and emotional needs.
Two studies were conducted to research the effectiveness of interactive virtual reality sessions in nature - using Virry VR - for emotional regulation on children with significant socioemotional needs (i.e autism spectrum disorder and/ or ADHD). The studies revealed two common areas of change after the implementation of a VR intervention: improved emotional self-awareness and targeted emotion management. Further implications of the research included the observation that participants had access to a therapeutic-debrief session that is time-efficient and cost-effective in comparison to 1:1 therapy. The studies were supervised by Professor Vivian Hill, from the Department of Psychology and Human Development at the UCL Institute of Education.
We have already investigated the application of our product, Virry Life, in several areas, but would like to invite researchers to collaborate on investigating the use of Virry VR further in the following areas:
— Epigenetics
— looking at how meditation changes gene expression.
— Treatment of ADHD symptoms in children and teenagers.
— Pain reduction for patients/ people living with chronic pain.
— Improving the quality of life of dementia patients.
— Improving dementia patient’s memory.
— Improving mental health and emotional balance at high risk companies.
— Decreasing the subjective age of older adults.
— Depression.
— Anxiety.
— How psychological health can be improved by exposure to nature and wildlife.
— Improving empathy and ecocentrism.
.svg)
